By Kyle Morris

Shares in ImmuPharma PLC jumped 16% on Wednesday after the company said that it has received Food and Drug Administration confirmation for a pre-investigational new drug meeting on May 16 to consider a Phase 2/3 adaptive trial study protocol for its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy.

The company said that a new investigational new drug submission is required as this will be the first time that P140 is to be studied in humans for the indication of CIDP.

Shares at 0716 GMT were up 0.35 pence at 2.50 pence.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

April 12, 2023 03:47 ET (07:47 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Immupharma Charts.